Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Apply to the University of Wyoming apply now

Global Resource Navigation

Visit Campus
Download UW Viewbook
Give to UW
Menu

Contact Us

Wyoming Drug Utilization Review (WY-DUR)

Dept. 3375

1000 E. University Ave.

Laramie, WY 82070

Phone: 307-766-6750

Fax: 307-766-2953

Email: lgm@uwyo.edu

Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

The Wyoming Department of Health is conducting a survey concerning the use and barriers to use of 17-alpha hydroxyprogesterone in pregnant women.  If you routinely provide prenatal care for your pregnant patients, please participate in this survey.

New Drug Review: Possible P & T Committee Decisions (May 2015)

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org. 

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 2, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the August 10, 2017 P & T Committee meeting.

  • Dupixent will be limited to adults and listed as a step 3 agent for atopic dermatitis on the preferred drug list.

  • Esbriet will be limited to its indication of idiopathic pulmonary fibrosis.  In addition, a pulmonary consult within the previous year will be required for approval.

  • Tymlos will require a 12 month trial and failure of other osteoporosis therapy prior to approval.

  • Vosevi is the first medication approved for retreatment of Hepatitis C.  This medication will require prior authorization.  It is important to note that failure due to non-compliance will not be considered for approval.  A documented SVR12 following previous therapy will be required for approval of retreatment.

  • Ocrevus will be approved for those with primary progressive multiple sclerosis.  For those with relapsing forms, trial and failure of traditional medications will be required prior to approval.

  • The Department of Health will conduct cost analyses on Kevzara and Siliq to determine placement on the preferred drug list.  There is no evidence of a benefit of either drug over existing medications in their respective classes. 

  • Austedo, Ingrezza, and Xadago will be limited to their indications.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to November 1, 2017.

P & T Committee Meeting Dates

Agenda August 10, 2017 (revised August 1, 2017)

Minutes August 10, 2017

2017 Meetings

Thursday, February 9; Wednesday, May 10; Thursday, August 10; Thursday, November 9

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.


Share This Page:


Contact Us

Wyoming Drug Utilization Review (WY-DUR)

Dept. 3375

1000 E. University Ave.

Laramie, WY 82070

Phone: 307-766-6750

Fax: 307-766-2953

Email: lgm@uwyo.edu

1000 E. University Ave. Laramie, WY 82071
UW Operators (307) 766-1121 | Contact Us | Download Adobe Reader

Twitter Icon Youtube Icon Instagram Icon Facebook Icon

Accreditation | Emergency Preparedness | Employment at UW | Gainful Employment | Privacy Policy | Accessibility Accessibility information icon